S100A4 Is a Targetable Regulator of Immune Suppression in Glioblastoma

Glioblastoma (GBM) is a highly aggressive brain tumor that remains largely refractory to immunotherapy owing to a profoundly immunosuppressive tumor microenvironment (TME). Here, we use mouse models of GBM to identify S100A4 as an actionable regulator of immune suppression and demonstrate that its inhibition converts GBM into an immunotherapy-responsive state. Genetic knockdown of S100a4 in glioma cells reprogrammed the GBM TME, enhancing CD8⁺ T cell infiltration and effector function while promoting maturation of antigen-presenting cells. These changes translated into significant survival benefits across diverse molecular subtypes of GBM. Therapeutically, a novel S100A4/Transferrin Receptor (TfR) bispecific antibody phenocopied S100a4-KD and showed significant therapeutic efficacy, particularly in combination with PD-1 blockade. Notably, BsA+anti-PD1 combination treatment generated tertiary lymphoid-like structures in GBM. Together, these findings establish S100A4 as a targetable driver of immune evasion in GBM and provide a translational strategy for overcoming resistance to immunotherapy in this lethal disease.

Authors

Institutions

Publication Details

Journal
bioRxiv (Cold Spring Harbor Laboratory)
Published
2026-11-12
DOI
https://doi.org/10.64898/2026.11.10.765528
Primary Topic
Glioma Diagnosis and Treatment
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

S100A4 Is a Targetable Regulator of Immune Suppression in Glioblastoma

Fransisca Leonard, Nourhan Abdelfattah, Kyuson Yun, Zhiqiang An et al.
bioRxiv (Cold Spring Harbor Laboratory)
Glioma Diagnosis and Treatment
preprint

S100A4 Is a Targetable Regulator of Immune Suppression in Glioblastoma

Fransisca Leonard, Nourhan Abdelfattah, Kyuson Yun, Zhiqiang An, Maryam Faisal, Dante Jimenez, Han Nhat Tran, Jia-Shiun Leu, José Maldonado, Reece Kang, Thomas K. S. Wong, Ningyan Zhang, Sung Yun Jung, Yaqoob Ali, Sinem Gulnap, Wei Xiong
preprint en

Abstract

Glioblastoma (GBM) is a highly aggressive brain tumor that remains largely refractory to immunotherapy owing to a profoundly immunosuppressive tumor microenvironment (TME). Here, we use mouse models of GBM to identify S100A4 as an actionable regulator of immune suppression and demonstrate that its inhibition converts GBM into an immunotherapy-responsive state. Genetic knockdown of S100a4 in glioma cells reprogrammed the GBM TME, enhancing CD8⁺ T cell infiltration and effector function while promoting maturation of antigen-presenting cells. These changes translated into significant survival benefits across diverse molecular subtypes of GBM. Therapeutically, a novel S100A4/Transferrin Receptor (TfR) bispecific antibody phenocopied S100a4-KD and showed significant therapeutic efficacy, particularly in combination with PD-1 blockade. Notably, BsA+anti-PD1 combination treatment generated tertiary lymphoid-like structures in GBM. Together, these findings establish S100A4 as a targetable driver of immune evasion in GBM and provide a translational strategy for overcoming resistance to immunotherapy in this lethal disease.

bioRxiv (Cold Spring Harbor Laboratory)
Baylor College of Medicine (US), Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases (US), Houston Methodist Research Institute (US)
Good health and well-being
Glioma Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon